Recent developments in ovarian cancer genetics

Current Opinion in Obstetrics and Gynecology

Volumn 16, Issue 1, 2004, Pages 79-85

  Barnett, Ginger L ^a   Friedrich, Christopher A ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

BRCA1; BRCA2; Breast cancer; Genetic counseling; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CHECKPOINT KINASE 2; NUCLEOTIDE;

ALLELE; BREAST CANCER; CANCER GENETICS; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; ETHNIC GROUP; GENE FREQUENCY; GENE MUTATION; GENETIC COUNSELING; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; GYNECOLOGY; HEALTH INSURANCE; HIGH RISK POPULATION; HUMAN; MAMMOGRAPHY; MUTATIONAL ANALYSIS; OVARY CANCER; PATIENT CARE; PEER REVIEW; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SOCIAL ASPECT;

BRCA1 PROTEIN; BRCA2 PROTEIN; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MUTATION; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC;

EID: 1242272126     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200402000-00014     Document Type: Review

References (31)

1. Narod SA, Boyd J. Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer. Curr Opin Obstet Gynecol 2002; 14:19-26. This is a comprehensive review of the clinical aspects of hereditary ovarian cancer, with thorough reviews of management options based on clinical outcome and treatment effect studies.
2. Wooster R, Weber BL. Genomic medicine: breast and ovarian cancer. N Engl J Med 2003; 348:2339-2347. This exhaustive review covers important genetic discoveries related to breast and ovarian cancer, describes the application of genomics technologies to identify additional susceptibility genes, and presents early applications of molecular profiling using microarrays.
3. Olopade OI, Fackenthal JD, Dunston G, et al. Breast cancer genetics in African Americans. Cancer 2002; 97 (Suppl. 1):236-245.
4. Mullineaux LG, Castellano TM, Shaw J, et al. Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado. Cancer 2003; 98:597-502. This is an example of how the discovery of a founder mutation in a population can simplify genetic screening for members of that population.
5. Berry D, Iversen E, Gudbjartssan D, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002; 20:2701-2712.
6. Casadei S, Falcini F, Naldoni C, et al. Population-based screening for hereditary breast cancer in a region of north-central Italy. Int J Mol Med 2002; 10:299-305.
7. King, MC, Marks JH, Mandell JB, and the New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302:643-646. This is a large study that gave fairly definitive risk values for mutation carriers. The unusual finding was the increased risk of breast cancer in different birth cohorts, suggesting environmental modification(s) of the increased genetic risk.
8. Sng J-H, Ali AB, Lee SC, et al. BRCA1 c.2845insA is a recurring mutation with a founder effect in Singapore Malay women with early onset breast/ ovarian cancer. J Med Genet 2003; 40:e117. Available at http://www. jmedgenet.com/cgi/ content/full/40/10/e117, accessed 23 November 2003. This is the first report of mutation frequencies in this ethnic group, with one common mutation found.
9. Richards MPM, Ponder M, Pharoah P, et al. Issues of consent and feedback in a genetic epidemiological study of women with breast cancer. J Med Ethics 2003; 29:93-96.
10. Hallowell N, Foster C, Eeles R, et al. Balancing autonomy and responsibility: the ethics of generating and disclosing genetic information. J Med Ethics 2003; 29:74-83. This study is a nice summary for non-geneticists of the complications encountered when working with one patient who subsequently works with relatives to transmit information about the relatives' risk status.
11. Lobb EA, Butow PN, Meiser B, et al. Tailoring communication in consultations with women from high-risk breast cancer families. Br J Cancer 2002; 87:502-508.
12. Lehmann LS, Weeks JC, Klar N, Garber JE. A population-based study of Ashkenazi Jewish women's attitudes toward genetic discrimination and BRCA1/2 testing. Genet Med 2002; 4:346-352.
13. Hartenbach EM, Becker JM, Grosen EA, et al. Progress of a comprehensive familial cancer genetic counseling program in the era of BRCA1 and BRCA2. Genet Test 2002; 6:75-78.
14. Skinner CS, Schildkraut JM, Berry D, et al. Pre-counseling education materials for BRCA testing: does tailoring make a difference? Genet Test 2002; 6:93-105. This study demonstrates the advantages of personalized teaching materials for patients.
15. Armstrong K, Stopfer J, Calzone K, et al. What does my doctor think? Preferences for knowing the doctor's opinion among women considering clinical testing for BRCA1/2 mutations. Genet Test 2002; 6:115-118. This study was the first to measure patients' interest in their doctor's opinion about the appropriateness of genetic testing. Physicians should take note that many patients are not interested in their doctor's opinion, but would rather make decisions regarding testing on their own.
16. Bish A, Sutton S, Jacobs C, et al. Changes in psychological distress after cancer genetic counseling: a comparison of affected and unaffected women. Br J Cancer 2002; 86:43-50.
17. Schwartz MD, Peshkin BN, Hughes C, et al. Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol 2002; 20:514-520.
18. Lerman C, Hughes C, Croyle RT, et al. Prophylactic surgery decision and surveillance practices one year following BRCA1/2 testing. Prevent Med 2000; 31:75-80.
19. Isaacs C, Peshkin B, Schwartz M, et al. Breast and ovarian cancer screening practices in healthy women with a strong family history of breast or ovarian cancer. Breast Cancer Res Treatment 2002; 71:103-112.
20. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002; 20:1260-1268.
21. Peterson E, Milliron K, Lewis K, et al. Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol, Biomarkers Prevent 2002; 11:79-87. This study confirms other reports of the high level of concern patients have regarding the perceived threats to their own insurability and that of their relatives.
22. Mehnert A, Bergelt C, Koch U. Knowledge and attitudes of gynecologists regarding genetic counseling for hereditary breast and ovarian cancer. Patient Educ Counsel 2003; 49:183-188.
23. Bergman A, Engwall Y, Lundberg J, et al. Mutations spectrum of the BRCA1 and BRCA2 genes in western Sweden [Abstract]. Am J Hum Genet 2003; 73:362.
24. Baumbach L, Gayol L, Monteiro L, et al. BRCA1/BRCA2 missense mutations in African-American breast cancer patients [Abstract]. Am J Hum Genet 2003; 73:364.
25. Claes K, Poppe B, Coene I, et al. BRCA1/2 mutation spectrum and frequencies in Belgian breast/ovarian cancer families [Abstract]. Am J Hum Genet 2003; 73:365.
26. Phelan CM, Lubinski J, Ghadirian P, et al. Cancer variation associated with the position of BRCA2 gene mutation [Abstract]. Am J Hum Genet 2003; 73:413.
27. Marroni F, Aretini P, Bailey-Wilson JE, et al. Unbiased estimates of breast and ovarian cancer penetrances in BRCA1/2 mutation carriers using genetic test results [Abstract]. Am J Hum Genet 2003; 73:378.
28. Pasini B, Manoukian S, Pensotti V, et al. Screening for BRCA1 and BRCA2 germ line point mutations in 600 Italian families with breast and/or ovarian cancer: mutation prevalence according to phenotype [Abstract]. Am J Hum Genet 2003; 73:408.
29. Wood ME, Grossman CI, McKinnon WC, et al. Cancer screening adherence in breast/ovarian cancer families [Abstract]. Am J Hum Genet 2003; 73:410.
30. Moisan AM, Fortin J, Dumont M, et al. INHERIT BRCAs. No evidence of recurrent BRCA1/2 genomic rearrangement in high risk French-Canadian breast/ovarian cancer families [Abstract]. Am J Hum Genet 2003; 73:417.
31. Baysal BE, DeLoia JA, Goodman MT, et al. Analysis of CHEK2 for ovarian cancer susceptibility [Abstract]. Am J Hum Genet 2003; 73:493.